James Sabry at #JPM24 (Brian Benton Photography)
May 28, 2024 04:09 AM EDTUpdated 06:08 AM
People
Bioregnum

Af­ter 14 years call­ing part­ner­ing shots at Genen­tech/Roche, James Sabry is head­ed back in­to the biotech fray

James Sabry, the long­time doyen of biotech deal­mak­ers from his glob­al perch at Roche/Genen­tech, is jump­ing to the US biotech scene.

The Basel-based phar­ma gi­ant …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Bio­haven's myo­statin in­hibitor miss­es pri­ma­ry end­point in spinal mus­cu­lar at­ro­phy tri­al

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

A service from the Financial Times